LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Hind, Daniel; Kaklamanou, Daphne; Beever, Dan; Webster, Rosie; Lee, Ellen; Barkham, Michael; Cooper, Cindy L (2016)
Publisher: BioMed Central
Journal: BMC Psychiatry
Languages: English
Types: Article
Subjects: Reproducibility of Results, Research Article, Multiple Sclerosis, Chronic Disease, Psychometrics, Depression, Psychiatry and Mental health
Background: The prevalence of depression in people with multiple sclerosis (PwMS) is high; however, symptoms common to both conditions makes measurement difficult. There is no high quality overview of validation studies to guide the choice of depression inventory for this population.\ud \ud Methods: A systematic review of studies validating the use of generic depression inventories in people with MS was conducted using MEDLINE and PsycINFO. Studies validating the use of depression inventories in PwMS and published in English were included; validation studies of tests for cognitive function and general mental health were excluded. Eligible studies were then quality assessed using the COSMIN checklist and findings synthesised narratively by instrument and validity domain.\ud \ud Results: Twenty-one studies (N=5,991 PwMS) evaluating 12 instruments were included in the review. Risk of bias varied greatly between instrument and validity domain. \ud \ud Conclusions: The review of validation studies was constrained by poor quality reporting and outcome reporting bias. Well-conducted evaluations of some instruments are unavailable for some validity domains. This systematic review provides an evidence base for trade-offs in the selection of an instrument for assessing self-reported symptoms of depression in research or clinical practice involving people with MS. We make detailed and specific recommendations for where further research is needed.\ud \ud Registration: PROSPERO CRD42014010597\ud \ud Keywords\ud Depression; Multiple Sclerosis; Reproducibility of Results; Psychometrics; Chronic Disease
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Rudick R, Cohen J, Weinstock-Guttman B, Kinkel R, Ransohoff R. Management of multiple sclerosis. N Engl J Med. 1997;337:1604-11.
    • 2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-17.
    • 3. Benito-León J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil. 2003;25:1291-303.
    • 4. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005;76:469-75.
    • 5. Hind D, O'Cathain A, Cooper CL, Parry GD, Isaac CL, Rose A, Martin L, Sharrack B. The acceptability of computerised cognitive behavioural therapy for the treatment of depression in people with chronic physical disease: a qualitative study of people with multiple sclerosis. Psychol Health. 2010;25: 699-712.
    • 6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM). Washington, DC: American Psychiatric Association; 1994.
    • 7. Mohr DC, Goodkin DE, Likosky W, Beutler L, Gatto N, Langan MK. Identification of Beck Depression Inventory items related to multiple sclerosis. J Behav Med. 1997;20:407-14.
    • 8. Mayou R, Hawton K. Psychiatric disorder in the general hospital. Br J Psychiatry. 1986;149:172-90.
    • 9. Endicott J. Measurement of depression in patients with cancer. Cancer. 1984;53(10 Suppl):2243-8.
    • 10. Feldman E, Mayou R, Hawton K, Arden M, Smith EB. Psychiatric disorder in medical in-patients. QJM. 1987;63:405-12.
    • 11. House A. Mood disorders in the physically ill-problems of definition and measurement. J Psychosom Res. 1988;32:345-53.
    • 12. Dew MA, Ragni MV, Nimorwicz P. Infection with human immunodeficiency virus and vulnerability to psychiatric distress. A study of men with hemophilia. Arch Gen Psychiatry. 1990;47:737-44.
    • 13. Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, Bever C, Schiffer RB, Gronseth GS, Narayanaswami P. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the guideline development subcommittee of the American academy of neurology. Neurology. 2014;82:174-81.
    • 14. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ. 2001;323:42-6.
    • 15. Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from descriptions of treatment in trials and reviews? BMJ Br Med J. 2008;336:1472-4.
    • 16. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HCW. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010;63:737-45.
    • 17. Webster R, Hind D, Kaklamanou D, Beever D, Barkham M, Cooper C. The assessment of depression in people with multiple sclerosis: a systematic review of psychometric validation studies. PROSPERO 2014:CRD42014010597. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014010597.
    • 18. Gold SM, Schulz H, Mönch A, Schulz K-H, Heesen C. Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Mult Scler. 2003;9:404-10.
    • 19. Horton M, Rudick RA, Hara-Cleaver C, Marrie RA. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology. 2010; 35:83-90.
    • 20. Rabins PV, Brooks BR. Emotional disturbance in multiple sclerosis patients: validity of the General Health Questionnaire (GHQ). Psychol Med. 1981;11:425-7.
    • 21. Smith RA, Berg JE, Pope LE, Callahan JD, Wynn D, Thisted RA. Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler. 2004;10:679-85.
    • 22. Randolph JJ, Arnett PA, Higginson CI, Voss WD. Neurovegetative symptoms in multiple sclerosis: relationship to depressed mood, fatigue, and physical disability. Arch Clin Neuropsychol. 2000;15:387-98.
    • 23. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HCW. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19:539-49.
    • 24. Aikens JE, Reinecke MA, Pliskin NH, Fischer JS, Wiebe JS, McCracken LM, Taylor JL. Assessing depressive symptoms in multiple sclerosis: is it necessary to omit items from the original Beck Depression Inventory? J Behav Med. 1999;22:127-42.
    • 25. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829-35.
    • 26. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297-334.
    • 27. Nunnally J. Psychometric Theory. 2nd ed. New York: McGraw-Hill; 1978.
    • 28. Fleiss J. The design and analysis of clinical experiments - Wiley classics library edition. New York: Wiley; 1986.
    • 29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.
    • 30. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model A Multidiscip J. 1999;6:1-55.
    • 31. Nicholl CR, Lincoln NB, Francis VM, Stephan TF. Assessment of emotional problems in people with multiple sclerosis. Clin Rehabil. 2001;15:657-68.
    • 32. Lykouras L, Oulis P, Adrachta D, Daskalopoulou E, Kalfakis N, Triantaphyllou N, Papageorgiou K, Christodoulou GN. Beck Depression Inventory in the detection of depression among neurological inpatients. Psychopathology. 1998;31:213-9.
    • 33. Amtmann D, Kim J, Chung H, Bamer AM, Askew RL, Wu S, Cook KF, Johnson KL. Comparing CESD-10, PHQ-9, and PROMIS depression instruments in individuals with multiple sclerosis. Rehabil Psychol. 2014;59:220-9.
    • 34. Avasarala JR, Cross AH, Trinkaus K. Comparative assessment of Yale single question and Beck Depression Inventory Scale in screening for depression in multiple sclerosis. Mult Scler. 2003;9:307-10.
    • 35. Beeney JE, Arnett PA. Endorsement of self-report neurovegetative items of depression is associated with multiple sclerosis disease symptoms. J Int Neuropsychol Soc. 2008;14:1057-62.
    • 36. Benedict RHB, Fishman I, McClellan MM, Bakshi R, Weinstock-Guttman B. Validity of the Beck Depression Inventory-fast screen in multiple sclerosis. Mult Scler. 2003;9:393-6.
    • 37. Chang C-H, Nyenhuis DL, Cella D, Luchetta T, Dineen K, Reder AT. Psychometric evaluation of the Chicago multi scale depression inventory. Mult Scler. 2003;9:160-70.
    • 38. Mohr DC, Hart SL, Julian L, Tasch ES. Screening for depression among patients with multiple sclerosis: two questions may be enough. Mult Scler. 2007;13:215-9.
    • 39. Moran PJ, Mohr DC. The Validity of Beck Depression Inventory and Hamilton rating scale for depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med. 2005;28:35-41.
    • 40. Nyenhuis DL, Rao SM, Zajecka JM, Luchetta T, Bernardin L, Garron DC. Mood disturbance versus other symptoms of depression in multiple sclerosis. J Int Neuropsychol Soc. 1995;1:291-6.
    • 41. Strober LB, Arnett PA. Assessment of depression in multiple sclerosis: development of a “trunk and branch” model. Clin Neuropsychol. 2010;24: 1146-66.
    • 42. Honarmand K, Feinstein A. Validation of the hospital anxiety and depression scale for use with multiple sclerosis patients. Mult Scler. 2009;15:1518-24.
    • 43. Pandya R, Metz L, Patten SB. Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment. Psychosomatics. 2005;46:131-4.
    • 44. Patten SB, Lavorato DH, Metz LM. Clinical correlates of CES-D depressive symptom ratings in an MS population. Gen Hosp Psychiatry. 2005;27:439-45.
    • 45. Patten SB, Berzins S, Metz LM. Challenges in screening for depression in multiple sclerosis. Mult Scler. 2010;16:1406-11.
    • 46. Sjonnesen K, Berzins S, Fiest KMM, Bulloch AG, Metz LM, Thombs BD, Patten SB. Evaluation of the 9-item Patient Health Questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis. Postgrad Med. 2012;124:69-77.
    • 47. Sullivan MJ, Weinshenker B, Mikail S, Bishop SR. Screening for major depression in the early stages of multiple sclerosis. Can J Neurol Sci. 1995; 22:228-31.
    • 48. Verdier-Taillefer MH, Gourlet V, Fuhrer R, Alpérovitch A. Psychometric properties of the center for epidemiologic studies-depression scale in multiple sclerosis. Neuroepidemiology. 2001;20:262-7.
    • 49. Solari A, Motta A, Mendozzi L, Aridon P, Bergamaschi R, Ghezzi A, Mancardi GL, Milanese C, Montanari E, Pucci E. Italian version of the Chicago multiscale depression inventory: translation, adaptation and testing in people with multiple sclerosis. Neurol Sci. 2003;24:375-83.
    • 50. Vahter L, Kreegipuu M, Talvik T, Gross-Paju K. One question as a screening instrument for depression in people with multiple sclerosis. Clin Rehabil. 2007;21:460-4.
    • 51. Wright BD, Linacre JM. Reasonable mean-square fit values. Rasch Meas Trans. 1994;8:370.
    • 52. Manoj H, Sivan M. Study to establish the usefulness of the one question “Are you depressed?” in screening people with multiple sclerosis for depression. Clin Rehabil. 2007;21:1143.
    • 53. Stevinson C, Lawlor DA. Searching multiple databases for systematic reviews: added value or diminishing returns? Complement Ther Med. 2004;12:228-32.
    • 54. Watson RJ, Richardson PH. Identifying randomized controlled trials of cognitive therapy for depression: comparing the efficiency of Embase, Medline and PsycINFO bibliographic databases. Br J Med Psychol. 1999;72(Pt 4):535-42.
    • 55. Löhönen J, Isohanni M, Nieminen P, Miettunen J. Coverage of the bibliographic databases in mental health research. Nord J Psychiatry. 2010;64:181-8.
    • 56. Beckles Z, Glover S, Ashe J, Stockton S, Boynton J, Lai R, Alderson P. Searching CINAHL did not add value to clinical questions posed in NICE guidelines. J Clin Epidemiol. 2013;66:1051-7.
    • 57. Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D. The effect of Englishlanguage restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28:138-44.
    • 58. Hopewell S, McDonald S, Clarke Mike J, Egger M. Grey literature in metaanalyses of randomized trials of health care interventions. Cochrane Database Syst Rev. 2007.
    • 59. Mokkink LB, Terwee CB, Stratford PW, Alonso J, Patrick DL, Riphagen I, Knol DL, Bouter LM, de Vet HCW. Evaluation of the methodological quality of systematic reviews of health status measurement instruments. Qual Life Res. 2009;18:313-33.
    • 60. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan A-W, Cronin E, Decullier E, Easterbrook PJ, Von Elm E, Gamble C, Ghersi D, Ioannidis JPA, Simes J, Williamson PR. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One. 2008;3:e3081.
    • 61. Chan A-W, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ. 2005; 330:753.
    • 62. Gargon E, Williamson PR, Altman DG, Blazeby JM, Clarke M. The COMET Initiative database: progress and activities from 2011 to 2013. Trials. 2014;15:279.
    • 63. Strober LB. Depression in Multiple sclerosis (MS): The distinction between MS and depressive symptomatology and utility of self-report instruments. Pennsylvania: The Pennsyvania State University; 2007.
    • 64. Butt Z, Demaree HA. Assessing depression in patients with multiple sclerosis. Int J MS Care. 2004;6:116-22.
    • 65. Beck A, Steer R, Brown G. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
    • 66. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med. 2011;9:86.
    • 67. Connell J, O'Cathain A, Brazier J. Measuring quality of life in mental health: are we asking the right questions? Soc Sci Med. 2014;120:12-20.
    • 68. Ericsson KA, Simon HA. Protocol Analysis: Verbal Reports as Data, Revised Edition. Cambridge: MA: MIT Press; 1993.
    • 69. French DP, Hevey D. What do people think about when answering questionnaires to assess unrealistic optimism about skin cancer? A think aloud study. Psychol Health Med. 2008;13:63-74.
    • 70. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531-3.
  • No similar publications.

Share - Bookmark

Cite this article